PLEN-1 - Diversity, Equity, and Inclusion in Pharmacoepidemiology – The Role of Caste in Drug Utilization, Safety, and Therapeutic Risk Management
8:30 AM – 10:00 AM US Eastern Time
PLEN-1 - Plenary Session: Diversity, Equity, and Inclusion in Pharmacoepidemiology – the Role of Caste in Drug Utilization, Safety, and Therapeutic Risk Management
Location: PLEN-1
Concurrent Session 1
10:00 AM – 11:30 AM US Eastern Time
CW03 - Concurrent Workshops 1
10:00 AM – 11:30 AM US Eastern Time
WS-03 - Big Data in Health and Bioethics: A Call for a Comprehensive, Multi-disciplinary, ISPE Position
Location: WS-03
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
10:00 AM – 11:30 AM US Eastern Time
WS-11 - Outcome Measurements for External Comparator Arms: New Opportunities for Epidemiology Methods Application and Development
Location: WS-11
Methods in Pharmacoepidemiology
10:00 AM – 11:30 AM US Eastern Time
WS-13 - Polypharmacy: Problems and Solutions for Its Methodologic Challenges in Real-world Data
Location: WS-13
Methods in Pharmacoepidemiology
10:00 AM – 11:30 AM US Eastern Time
WS-15 - Real World Data in the Era of covid-19: The Devil in the Details. an ISPE RWE Task force/covid-19 Workgroup Symposium
Location: WS-15
Disease Epidemiology/Clinical Course
Oral Presentations Session 1
11:45 AM – 1:30 PM US Eastern Time
OP-03 - Confusion, Falls, and Fractures
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Confusion, Falls, and Fractures
Location: OP-03
11:45 AM – 1:30 PM US Eastern Time
OP-3A - Risk of Falls Following the Initiation of Antihypertensives in the Elderly: A Self-controlled Case Series in the UK
Location: OP-03
Geriatric Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-3B - Uncontrolled Pain and Risk for Depression and Behavioral Symptoms in Patients with Dementia
Location: OP-03
Geriatric Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-3C - Use of Medications with Anticholinergic and Sedative Properties and Fall-related Fractures Among Older Adults
Location: OP-03
Geriatric Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-3D - Bisphosphonate Use and Risk of Severe Acute Kidney Injury : A Self-controlled Case Series in Frail Elderly Patients in the UK
Location: OP-03
Geriatric Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-3E - Risk of Delirium Associated with Antimuscarinics in Older Adults: A Case-time-control Study
Location: OP-03
Geriatric Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-04 - COVID-19 Epidemiology: Risk Factors, Drug Exposures, and Outcomes
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: COVID-19 Epidemiology: Risk Factors, Drug Exposures, and Outcomes
Location: OP-04
11:45 AM – 1:30 PM US Eastern Time
OP-4A - Severe Obesity Is a Risk Factor for Mortality in Patients with COVID-19
Location: OP-04
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-4B - Predictors of Critical Care, Mechanical Ventilation, and Mortality Among Hospitalized Patients with COVID-19 in an Electronic Health Record Database
Location: OP-04
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-4C - Utilizing the National COVID Cohort Collaborative (N3C) to Evaluate Risk of Serious Outcomes with COVID-19 Among Chronically Immunosuppressed Persons
Location: OP-04
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-4D - Incidence and Risk Factors for Covid-related Urgent Medical Visits Among US Patients Diagnosed with COVID-19 in the Outpatient Setting
Location: OP-04
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-4E - Chronic Diseases, Health Conditions and Risk of covid-19-related Hospitalization and In-hospital Mortality During the First Wave of the Epidemic in France: A Cohort Study of 66 Million People
Location: OP-04
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-4F - Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized with Non-severe COVID-19: An Observational Analysis Emulating a Target Trial
Location: OP-04
Drug Effectiveness
11:45 AM – 1:30 PM US Eastern Time
OP-06 - Drug Utilization in Pain and Musculoskeletal Conditions
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Drug Utilization in Pain and Musculoskeletal Conditions
Location: OP-06
11:45 AM – 1:30 PM US Eastern Time
OP-6A - Utilization of Non-pharmacologic Pain Therapies Among Primary Care Physicians in the United States: A Cross-sectional Survey
Location: OP-06
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-6B - Prevalence of Osteoporosis and Its Treatment Among Women ≥50 in NHANES: 1999-2018
Location: OP-06
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-6C - Serum Vitamin D Levels and Incident Prescription Opioid Use Among Opioid-naïve Patients
Location: OP-06
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-6D - Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Location: OP-06
Biologics/Biosimilars
11:45 AM – 1:30 PM US Eastern Time
OP-6E - Primary Care Physicians’ Preparedness to Treat Opioid Use Disorder in the United States: A Cross-sectional Survey
Location: OP-06
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-09 - Heterogeneity in methods
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Heterogeneity in Methods
Location: OP-09
11:45 AM – 1:30 PM US Eastern Time
OP-9A - A New Method to Estimate the Total Cohort Size for Patient Recruitment in self-controlled Case Series Study
Location: OP-09
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-9B - Sessa Empirical Estimator (SEE): A Data-driven Method for Predicting the Duration of Pharmacological Prescriptions in Secondary Data Sources
Location: OP-09
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-9C - Graphical Representation of an Array of Quantitative Bias Analysis Scenarios for Differential Outcome Misclassification
Location: OP-09
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-9D - The Performance of Different Strategies to Manage Confounding in Cardinality Matching for Medical Device Epidemiology: A Simulation Study
Location: OP-09
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-9E - Use of Linked Databases for Improved Confounding Control: Considerations for Potential Selection Bias
Location: OP-09
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-9F - A Systematic Approach Towards Missing Lab Data in Electronic Health Records: A Case Study in Non-small Cell Lung Cancer and Multiple Myeloma
Location: OP-09
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-19 - Pregnancy: Wood for the trees
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Pregnancy: Wood for the Trees
Location: OP-19
11:45 AM – 1:30 PM US Eastern Time
OP-19A - Implication of Maternal Continuous Enrollment on Stillbirth Gestational Age Distributions and Maternal Characteristics in Medicaid Enrollees
Location: OP-19
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-19B - Feasibility of Using Healthcare Utilization Data to Identify Neurodevelopmental Disorders for Transgenerational Pharmacoepidemiology
Location: OP-19
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-19D - Validating an Optimized Live Birth Gestational Age Algorithm in a Nationwide Medicaid Sample and Quantifying the Misclassification of Exposure Due to Estimated Gestational Age
Location: OP-19
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-19E - Statistical Power for Use of Tree-based Scan Statistics for Surveillance of Infant Outcomes Following Maternal Perinatal Medication Use
Location: OP-19
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-19F - Use of Tree-based Scan Statistics for Surveillance of Infant Outcomes Following Maternal Perinatal Medication Use: A Propensity Score Matched Case Study
Location: OP-19
Pregnancy and Lactation
11:45 PM – 1:30 PM US Eastern Time
OP-19C - Fertility Rates in Women with Psoriasis and Psoriatic Arthritis: A Population-based Cohort Study
Location: OP-19
Pregnancy and Lactation
Oral Presentations Session 2
1:45 PM – 3:30 PM US Eastern Time
OP-14 - Opioids: A Globally Trending Topic
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Opioids: A Globally Trending Topic
Location: OP-14
1:45 PM – 3:30 PM US Eastern Time
OP-14A - Trends in Long-term Use of Prescribed Opioids in Norway 2010-2019
Location: OP-14
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-14B - Filled Prescriptions for Opioids Among Children and Adolescents – a Nationwide Study from 2010 to 2018
Location: OP-14
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-14C - Trends and Outcomes of Serious Complications Associated with Non-fatal Opioid Overdoses in Ontario, Canada
Location: OP-14
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-14D - Geographic Variation in the Use of Gabapentinoids and Opioids for Pain in a Commercially Insured Population in the United States
Location: OP-14
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-14E - Trajectories of Pregabalin Use and Their Association with Longitudinal Changes in Opioid and Benzodiazepine Daily Dose
Location: OP-14
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-14F - Prior Opioid Tolerance Among New Users of Transdermal Fentanyl in Taiwan, 2011-2018
Location: OP-14
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-18 - Pregnancy: Pick-n-mix
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Pregnancy: Pick-n-mix
Location: OP-18
1:45 PM – 3:30 PM US Eastern Time
OP-18A - Prescription Medication Use and Baseline Health Status of Women with Live Birth Deliveries in a National Data Network: The Sentinel Distributed Database Mother-infant Linkage Table
Location: OP-18
Pregnancy and Lactation
1:45 PM – 3:30 PM US Eastern Time
OP-18B - Increasing Prescriptions of Misoprostol Dispensed Before Delivery in Belgium (2003-2017): Evidence from Healthcare Administrative Database
Location: OP-18
Pregnancy and Lactation
1:45 PM – 3:30 PM US Eastern Time
OP-18C - Effects of Gadolinium-enhanced MRI Exposure During Pregnancy on Neonatal Intensive Care Unit Admission
Location: OP-18
Pregnancy and Lactation
1:45 PM – 3:30 PM US Eastern Time
OP-18D - Proton Pump Inhibitors in Pregnancy and Risk of Preeclampsia: A Nationwide Cohort Study of 1.9 Million Pregnancies
Location: OP-18
Pregnancy and Lactation
1:45 PM – 3:30 PM US Eastern Time
OP-18E - Validity of ICD-10 Z3A Codes for Estimating Date of Last Menstrual Period
Location: OP-18
Pregnancy and Lactation
1:45 PM – 3:30 PM US Eastern Time
OP-18F - COVID-19 Pharmacotherapy During Pregnancy: International Registry of Coronavirus Exposure in Pregnancy (IRCEP)
Location: OP-18
Pregnancy and Lactation
1:45 PM – 3:30 PM US Eastern Time
OP-22 - The Aging Heart
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: The Aging Heart
Location: OP-22
1:45 PM – 3:30 PM US Eastern Time
OP-22A - Risk of Myocardial Infarction, Stroke or Death in New Users of Intravitreal Aflibercept versus New Users of Intravitreal Ranibizumab: A Nationwide Cohort Study
Location: OP-22
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
1:45 PM – 3:30 PM US Eastern Time
OP-22C - Statin Discontinuation and Risk of Cardiovascular Events in Older People: A Population-based Cohort Study in Denmark
Location: OP-22
Geriatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-22D - Assessment of Co-medication Quality in Older Colorectal Cancer Patients at Hospital Discharge After Tumor Surgery and Its Associations with Chemotherapy-related Adverse Drug Reactions and 5-year Survival
Location: OP-22
Geriatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-22E - Comparative Risk of Cardiac Arrhythmias Associated with Acetylcholinesterase Inhibitor Use
Location: OP-22
Geriatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-22F - Risk of Cardiotoxicity Associated with Fluoropyrimidine-based Chemotherapy Among Older Colorectal Cancer Patients: A New User Cohort Study
Location: OP-22
Geriatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-24 - Trials and Errors
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Trials and Errors
Location: OP-24
1:45 PM – 3:30 PM US Eastern Time
OP-24A - Using Randomized Trial Data to Estimate Effects of Complex Treatment Regimens in Real-world Patients
Location: OP-24
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-24B - A Plasmode Simulation of Covariate Misclassification and Transportability
Location: OP-24
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-24C - The Effect of the Anticholinergic Properties of Antidepressants on the Incidence of Dementia: A Target Trial Emulation
Location: OP-24
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-24D - Stable Balancing Weights for Unanchored Matching-adjusted Indirect Comparisons and Targeting External Control Arm Estimands
Location: OP-24
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-24E - Linear Mixed Model and Multistate Markov Model to Compare Changes in Clinical Measurements over Time. a Blood Pressure Example
Location: OP-24
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-24F - Rank-based Weighting for Balancing on Median Baseline Characteristics in Matching Adjusted Indirect Comparisons (MAIC)
Location: OP-24
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-26 - Vaccines
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Vaccines
Location: OP-26
1:45 PM – 3:30 PM US Eastern Time
OP-26A - Evaluation of the Potential Confounding Effect of Shingles on the Risk of Guillain-barré Syndrome After Vaccination with the Recombinant Zoster Vaccine
Location: OP-26
Vaccines
1:45 PM – 3:30 PM US Eastern Time
OP-26C - Sensitivity Analysis of Design Choices for Estimating Incidence Rates of Adverse Events of Special Interest in Vaccine Safety
Location: OP-26
Vaccines
1:45 PM – 3:30 PM US Eastern Time
OP-26D - Effectiveness of Influenza Vaccination in Healthy Children: A Population-based Investigation
Location: OP-26
Vaccines
1:45 PM – 3:30 PM US Eastern Time
OP-26E - Background Incidence Rates of Adverse Events of Special Interest for COVID-19 Vaccine Monitoring
Location: OP-26
Vaccines
1:45 PM – 3:30 PM US Eastern Time
OP-26F - Vaccination and Acute Flares in Multiple Sclerosis: A Nationwide Case-crossover Study Using the French SNDS Health Care Databases
Location: OP-26
Vaccines
Concurrent Session 2
3:30 PM – 5:00 PM US Eastern Time
CW04 - Concurrent Workshops 2
3:30 PM – 5:00 PM US Eastern Time
WS-04 - COVID-19 Confidential: Enabling Trust in COVID-19 Research with Fit for Purpose Real-world Data
Location: WS-04
Methods in Pharmacoepidemiology
3:30 PM – 5:00 PM US Eastern Time
WS-05 - Drug Utilization Research in Africa: Challenges and Potential Solutions
Location: WS-05
Drug Utilization Research
3:30 PM – 5:00 PM US Eastern Time
WS-19 - Triangulating the Truth: State-of-the-art Sensitivity Analyses for Observational Research
Location: WS-19
Methods in Pharmacoepidemiology
Lightning Session 1
5:30 PM – 6:30 PM US Eastern Time
L-1 - Lightning Presentations Session 1
5:30 PM – 6:30 PM US Eastern Time
Lightning Presentations Session 1
Location: L-1
5:30 PM – 6:30 PM US Eastern Time
L-1 - Lightning Session 1
5:30 PM – 6:30 PM US Eastern Time
L-1A - Use of Remdesivir for COVID-19 in the Real World: An Analysis of US Electronic Medical Records
Location: L-1
Disease Epidemiology/Clinical Course
5:30 PM – 6:30 PM US Eastern Time
L-1B - Comparing Outcomes in Trial-eligible vs Real-world COVID-19 Patients: The Case of Invasive Mechanical Ventilation
Location: L-1
Disease Epidemiology/Clinical Course
5:30 PM – 6:30 PM US Eastern Time
L-1C - Outpatient-identified COVID-19 and Subsequent Hospitalized Thrombotic Events
Location: L-1
Disease Epidemiology/Clinical Course
5:30 PM – 6:30 PM US Eastern Time
L-1D - Patients Tell All: Using a Direct-to-patient Community Registry to Understand Patient Burden of COVID-19
Location: L-1
Disease Epidemiology/Clinical Course
5:30 PM – 6:30 PM US Eastern Time
L-1E - Marginal Structural Models with Latent Class Growth Modeling of Time-varying Treatment
Location: L-1
Methods in Pharmacoepidemiology
5:30 PM – 6:30 PM US Eastern Time
L-1F - Residual Bias and Indirect Covariate Balance in an Applied Comparison of Large-scale Propensity Score and Cardinality Matching
Location: L-1
Methods in Pharmacoepidemiology
5:30 PM – 6:30 PM US Eastern Time
L-1G - Characterizing Imbalance in the Tails of the Propensity Score Distribution
Location: L-1
Methods in Pharmacoepidemiology
5:30 PM – 6:30 PM US Eastern Time
L-1H - High-dimensional Propensity Score Approaches in Stata Using the Hdps Suite of Commands
Location: L-1
Methods in Pharmacoepidemiology
5:30 PM – 6:30 PM US Eastern Time
L-1J - Patterns of Antibiotic Prescription Among Adult Outpatients in Italy
Location: L-1
Drug Utilization Research
5:30 PM – 6:30 PM US Eastern Time
L-1K - Determinants of Antimalarial Prescription Patterns Among Health Care Providers in Public Health Facilities in Uasin Gishu County, Kenya
Location: L-1
Drug Utilization Research
5:30 PM – 6:30 PM US Eastern Time
L-1L - Co-utilization of Opioids and Non-benzodiazepine Sedative Hypnotics in U.S. Ambulatory Care Visits, 2006 – 2016
Location: L-1
Drug Utilization Research
5:30 PM – 6:30 PM US Eastern Time
L-1M - Early Uptake of New Molecular Entities Approved in 2017 in a Multisite National US Healthcare Data Network
Location: L-1
Drug Utilization Research
5:30 PM – 6:30 PM US Eastern Time
L-1N - Comparative Effectiveness of Bevacizumab versus Cetuximab in Patients with Metastatic Colorectal Cancer
Location: L-1
Drug Effectiveness
5:30 PM – 6:30 PM US Eastern Time
L-1P - Efficacy-effectiveness Gap for Standard First-line Treatment Of
metastatic Non-small Cell Lung Cancer Among Patients with Barriers to Care
Location: L-1
Drug Effectiveness
5:30 PM – 6:30 PM US Eastern Time
L-1Q - Acute Kidney Injury in Patients with Atrial Fibrillation Treated with Rivaroxaban or Warfarin: A Population-based Study in the United Kingdom
Location: L-1
Drug Effectiveness
5:30 PM – 6:30 PM US Eastern Time
L-1R - Long-acting Insulin Analogs versus Intermediate-acting Insulin and the Risk of Major Adverse Cardiovascular Events Among Patients with Type 2 Diabetes in the United Kingdom
Location: L-1
Drug Effectiveness
Lightning Session 2
6:30 PM – 7:30 PM US Eastern Time
L-2 - Lightning Presentations Session 2
6:30 PM – 7:30 PM US Eastern Time
Lightning Presentations Session 2
Location: L-2
6:30 PM – 7:30 PM US Eastern Time
L-2 - Lightning Session 2
6:30 PM – 7:30 PM US Eastern Time
L-2A - Changes in Purchases of Intensive Care Medicines During COVID-19 in Developed vs. Developing Countries
Location: L-2
Drug Utilization Research
6:30 PM – 7:30 PM US Eastern Time
L-2B - Collider Bias in COVID-19 Studies: Explaining the Smoking Paradox
Location: L-2
Methods in Pharmacoepidemiology
6:30 PM – 7:30 PM US Eastern Time
L-2C - The Prevalence of Hyperkalemia and Associated Clinical Characteristics and Outcomes Among Hospitalized COVID-19 Patients
Location: L-2
Health Economics/Outcomes Research
6:30 PM – 7:30 PM US Eastern Time
L-2D - Off-label Use of Potential Pharmacological Treatment for COVID-19: An Intensive Pharmacovigilance in Peru
Location: L-2
Pharmacovigilance
6:30 PM – 7:30 PM US Eastern Time
L-2E - Identification and Characterization of Fistulizing Crohn’s Disease in EHR Using Structured and Unstructured Data
Location: L-2
Methods in Pharmacoepidemiology
6:30 PM – 7:30 PM US Eastern Time
L-2F - Validation of Diagnosis Algorithms for Melanoma and Nonmelanoma Skin Cancer Among Patients with Parkinson’s Disease in the United States Medicare Database
Location: L-2
Methods in Pharmacoepidemiology
6:30 PM – 7:30 PM US Eastern Time
L-2G - An Algorithm to Derive Response and Progression Status Based on International Myeloma Working Group Response Criteria for Patients with Multiple Myeloma in a Real-world Database
Location: L-2
Methods in Pharmacoepidemiology
6:30 PM – 7:30 PM US Eastern Time
L-2H - Identification of Serostatus in Rheumatoid Arthritis Using ICD-10 Diagnosis Codes
Location: L-2
Disease Epidemiology/Clinical Course
6:30 PM – 7:30 PM US Eastern Time
L-2J - Cost-utility of Nivolumab for Treatment of Head and Neck Cancer from a Brazilian Public Health System Perspective
Location: L-2
Health Economics/Outcomes Research
6:30 PM – 7:30 PM US Eastern Time
L-2K - SGLT2 Inhibitors vs. GLP-1 Agonists: Comparative Progression of Renal Disease
Location: L-2
Health Economics/Outcomes Research
6:30 PM – 7:30 PM US Eastern Time
L-2L - Comparison of Medication Adherence Between Initiators of a Multi-drug Dispensing System & Users of Retail Pharmacy
Location: L-2
Health Economics/Outcomes Research
6:30 PM – 7:30 PM US Eastern Time
L-2M - Effects of Initiating a Multi-dose Drug Dispensing System on Medication Adherence
Location: L-2
Health Economics/Outcomes Research
6:30 PM – 7:30 PM US Eastern Time
L-2N - Prevalence of Myxoid /round Cell Liposarcoma (MRCLS) Among Children and Adults in the United States
Location: L-2
Disease Epidemiology/Clinical Course
6:30 PM – 7:30 PM US Eastern Time
L-2P - Atopic Eczema Associated Fracture Risk and Oral Corticosteroids: A Population-based Cohort Study
Location: L-2
Disease Epidemiology/Clinical Course
6:30 PM – 7:30 PM US Eastern Time
L-2Q - Trends in Sexually Transmitted Infections in the United States Ambulatory Care Clinics from 2005-2016
Location: L-2
Disease Epidemiology/Clinical Course
6:30 PM – 7:30 PM US Eastern Time
L-2R - Chemotherapy Relative Dose Intensity, Overall Survival, and Hematologic Toxicity in Solid-tumor Cancer Patients: A Literature Review and Meta-analysis
Location: L-2
Disease Epidemiology/Clinical Course
Plenary 1 - Repeat
8:00 PM – 9:30 PM US Eastern Time
PLEN-1B - REPEAT: Diversity, Equity, and Inclusion in Pharmacoepidemiology – The Role of Caste in Drug Utilization, Safety, and Therapeutic Risk Management
8:00 PM – 9:30 PM US Eastern Time
PLEN-1B - REPEAT: Diversity, Equity, and Inclusion in Pharmacoepidemiology – the Role of Caste in Drug Utilization, Safety, and Therapeutic Risk Management
Location: PLEN-1B
Tuesday, August 24, 2021
8:15 AM – 8:30 AM US Eastern Time
DAY2 - Welcome Session
8:15 AM – 8:30 AM US Eastern Time
Welcome Session
Location: DAY2
5:30 PM – 6:30 PM US Eastern Time
ICPE Student Social Event
5:30 PM – 6:30 PM US Eastern Time
SSE - ICPE Student Social Event
Plenary 2
8:30 AM – 10:00 AM US Eastern Time
PLEN-2 - Communicating COVID-19 Pharmacoepidemiological Research to Patients: Why is it important? How can we do it? What are the implications now and for the future?
8:30 AM – 10:00 AM US Eastern Time
PLEN-2 - Plenary Session: Communicating COVID-19 Pharmacoepidemiological Research to Patients: Why Is It Important? How Can We Do It? what Are the Implications Now and for the Future?
Location: PLEN-2
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
Concurrent Session 3
10:00 AM – 11:30 AM US Eastern Time
CW06 - Concurrent Workshops 3
10:00 AM – 11:30 AM US Eastern Time
WS-06 - From the Individual Through the Health System and Back: The Interdisciplinary Promise and Challenges of Digital Epidemiology for Improved Outcomes (An ISPE Digital Epidemiology SIG Endorsed Symposium)
Location: WS-06
Informatics
10:00 AM – 11:30 AM US Eastern Time
WS-07 - How to Emulate a Target Trial to Study the Effects of Treatments for and During Pregnancy
Location: WS-07
Pregnancy and Lactation
10:00 AM – 11:30 AM US Eastern Time
WS-08 - Lessons for Regulatory Decision-making from Real-world Data Trial Emulation Results
Location: WS-08
Drug Effectiveness
10:00 AM – 11:30 AM US Eastern Time
WS-09 - Methodological Approaches to Evaluating the Safety and Effectiveness of Multi-dose Coronavirus Disease 2019 (COVID-19) Vaccines Series
Location: WS-09
Vaccines
11:45 AM – 1:15 PM US Eastern Time
CW01 - Concurrent Workshops 4
11:45 AM – 1:15 PM US Eastern Time
WS-01 - A Call for ‘environmental Pharmacoepidemiology’: Medications, Global and Local Environments, and Health Outcomes
Location: WS-01
Methods in Pharmacoepidemiology
11:45 AM – 1:15 PM US Eastern Time
WS-02 - Believability of Real-world Evidence (RWE) for Informed Regulatory Decisions
Location: WS-02
Methods in Pharmacoepidemiology
11:45 AM – 1:15 PM US Eastern Time
WS-10 - New Frontiers in Computable Phenotyping for Medical Product Safety Evaluation
Location: WS-10
Methods in Pharmacoepidemiology
11:45 AM – 1:15 PM US Eastern Time
WS-20 - Using Real-world External Controls to Support Drug Approval: An Interactive Framework Using Oncology Trial and Real-world Data
Location: WS-20
Methods in Pharmacoepidemiology
Oral Presentations Session 3
1:45 PM – 3:30 PM US Eastern Time
OP-15 - Pharmacovigilance, Safety End Points, and Potpourri
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Pharmacovigilance, Safety End Points, and Potpourri
Location: OP-15
1:45 PM – 3:30 PM US Eastern Time
OP-15A - The Association Between Bariatric Surgery and Dupuytren Disease: A Cohort Study from Swedish Nationwide Healthcare Registries
Location: OP-15
Rare Disease
1:45 PM – 3:30 PM US Eastern Time
OP-15B - Selective Serotonin Reuptake Inhibitors and the Risk of Type 2 Diabetes Mellitus in Youths
Location: OP-15
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-15C - Comparing the Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib and TNF Inhibitors in Taiwan
Location: OP-15
Pharmacovigilance
1:45 PM – 3:30 PM US Eastern Time
OP-15D - Risk of Type 2 Diabetes Among Children Initiating Anticonvulsant Mood Stabilizers: Application of a Target Trial Approach
Location: OP-15
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-15E - Risk of Diabetic Ketoacidosis with Sodium-glucose transporter-2 Inhibitors Compared to Dipeptidyl peptidase-4 (DPP4) Inhibitors and Sulfonylureas in Patients with Type 2 Diabetes
Location: OP-15
Safety End Points
1:45 PM – 3:30 PM US Eastern Time
OP-15F - Comparable COVID-19 Outcomes with Current Use of GLP-1 Receptor Agonists, DPP-4 Inhibitors or SGLT-2 Inhibitors Among Patients with Diabetes Who Tested Positive for sars-cov-2
Location: OP-15
Disease Epidemiology/Clinical Course
1:45 PM – 3:30 PM US Eastern Time
OP-23 - Thinning the Blood: The Role of Anticoagulation and COVID-19
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Thinning the Blood: The Role of Anticoagulation and COVID-19
Location: OP-23
1:45 PM – 3:30 PM US Eastern Time
OP-23A - Heterogeneity and Temporal Variation in the Management of COVID-19: A Multinational Drug Utilisation Study Including 274,719 Hospitalised Patients From, the United States of America, China, Spain, and South Korea
Location: OP-23
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-23B - Real World Use of Anticoagulation Among Hospitalized Patients with COVID-19 in the United States
Location: OP-23
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-23C - Safety and Effectiveness of Prophylactic Anticoagulation for Prevention of COVID-19 Mortality: A Nationwide Cohort Study of Hospitalised Patients in the US
Location: OP-23
Drug Effectiveness
1:45 PM – 3:30 PM US Eastern Time
OP-23D - Anticoagulants and All-cause Mortality Among Hospitalized COVID-19 Patients
Location: OP-23
Drug Effectiveness
1:45 PM – 3:30 PM US Eastern Time
OP-23E - Use of Cardiovascular and Antidiabetic Drugs During COVID19 Epidemic in France
Location: OP-23
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-23F - Substantial Heterogeneity in the Management of Hospitalized Patient with COVID-19
Location: OP-23
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-25 - Two Hearts Beat as One: Evidence for Cardiovascular Safety from Real World Data and Clinical Trials
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Two Hearts Beat as One: Evidence for Cardiovascular Safety from Real World Data and Clinical Trials
Location: OP-25
1:45 PM – 3:30 PM US Eastern Time
OP-25A - Comparative Risk of Hospitalization for Heart Failure Among Patients with Xanthine Oxidase Inhibitors and Uricosuric Agents
Location: OP-25
Health Economics/Outcomes Research
1:45 PM – 3:30 PM US Eastern Time
OP-25B - Cardiovascular Risk in Users of Mirabegron Relative to Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-interventional, Real-world Data Safety Study
Location: OP-25
Safety End Points
1:45 PM – 3:30 PM US Eastern Time
OP-25C - Use of Low-dose Quetiapine and the Risk of Major Adverse Cardiovascular Events
Location: OP-25
Safety End Points
1:45 PM – 3:30 PM US Eastern Time
OP-25D - Jak Inhibitors and the Risk of Cardiovascular and Venous Thromboembolism Events Among Patients with Rheumatoid Arthritis: A Network Meta-analysis of Clinical Trials
Location: OP-25
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
1:45 PM – 3:30 PM US Eastern Time
OP-25F - Non-adherence and Non-persistence with Direct Oral Anticoagulants Increases the Risk of Stroke: Assessment in Three European Databases
Location: OP-25
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-27 - Validation and Algorithms: Getting the Present and Future Right
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Validation and Algorithms: Getting the Present and Future Right
Location: OP-27
1:45 PM – 3:30 PM US Eastern Time
OP-27A - Validity of Electronic Health Records-based Measures for COVID-19 Hospitalization and Severe Outcomes
Location: OP-27
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-27B - Death Documentation Lag in COVID-19 Electronic Health Record (EHR) Suggests Caution in Near-real-time Analysis
Location: OP-27
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-27C - Shifting the Traditional Model of Analysing Downloaded Electronic Health Records to the Novel Open-source Analytics Opensafely Platform
Location: OP-27
Informatics
1:45 PM – 3:30 PM US Eastern Time
OP-27D - Use of an EHR to Inform a Claims-based Algorithm to Categorize Inpatient COVID-19 Severity
Location: OP-27
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-27E - Categorization of COVID-19 Severity to Determine Mortality Risk
Location: OP-27
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-27F - Development and Validation of an Algorithm to Estimate the Risk of Severe Complications of COVID-19 to Prioritise Vaccination
Location: OP-27
Disease Epidemiology/Clinical Course
1:45 PM – 3:30 PM US Eastern Time
OP-28 - You gave the kids what? International use, policies, and outcomes in pediatric pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: You Gave the Kids What? International Use, Policies, and Outcomes in Pediatric Pharmacoepidemiology
Location: OP-28
1:45 PM – 3:30 PM US Eastern Time
OP-28A - Early Life Antibiotic Exposure and Incident Chronic Diseases in Childhood
Location: OP-28
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-28B - Antibiotic Prescribing in Children Aged 0–6 Years in Germany: Assessing Regional Variations and Potential Explanations Based on Claims Data
Location: OP-28
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-28C - Prescribed Medicine Use in a Nationwide Sample of Australian Children: Extent of Off-label Use
Location: OP-28
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-28D - General Practitioner Prescribing Trends Among Pediatric Patients in the United Kingdom: 1998-2018
Location: OP-28
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-28E - Visualizing Inappropriate Antibiotic Use Following Otitis Media in Children in the United States
Location: OP-28
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-28F - Impact of Drug-related Regulations on Codeine Use Among Children in Taiwan: A Nationwide Interrupted Time Series Analysis from 2005 to 2018
Location: OP-28
Pediatric Pharmacoepidemiology
Spotlight Posters 1
3:30 PM – 4:45 PM US Eastern Time
SP01 - Spotlight Posters: Adherence
3:30 PM – 4:45 PM US Eastern Time
SP01 - Spotlight Posters: Adherence
Location: SP01
3:30 PM – 4:45 PM US Eastern Time
SP0K - Impact of Lipid Lowering Therapy Modifications on Medication Adherence in Older Adults
Location: SP01
Health Economics/Outcomes Research
3:30 PM – 4:45 PM US Eastern Time
SP01A - Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon Like Peptide 1 Agonists in a Large Integrated Healthcare System
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01B - Comparing FOLFOX Delivery in Trial and Real-world Populations Using Longitudinal Cumulative Dose
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01C - Low Persistence of Antipsychotic Therapy in Parkinson Disease – Intolerance, Ineffectiveness, or Inertia?
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01D - Trajectories of Oral Budesonide Use in Crohn's Disease Cohort of Tuscan Patients (Italy)
Location: SP01
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP01E - Factors Associated with Adherence to Newly Initiated JAK Inhibitors in Rheumatoid Arthritis Patients
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01F - Pharmacological and Epidemiological Considerations While Constructing Drug Treatment Episodes Using Observational Data Retrospectively Collected: A Simulation Study
Location: SP01
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP01G - Comparison of Measures for Medication Adherence of Antihypertensive Drugs Using National Health Insurance Claims Data
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01H - Adherence and Associated Factors of Treatment Regimen in Drug-susceptible tuberculosis Patients
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01J - Antihypertensive and Lipid-lowering Drugs Usage After Primary Stroke
Location: SP01
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP02 - Spotlight Posters: ASPEN
3:30 PM – 4:45 PM US Eastern Time
SP02 - Spotlight Posters: ASPEN
Location: SP02
3:30 PM – 4:45 PM US Eastern Time
SP02A - Tramadol Dominating the Longitudinal Trajectories of Chronic Opioid Prescribing and Co-medication in Non-cancer Patients in Taiwan
Location: SP02
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP02B - Active Surveillance of Hemovigilance in a Tertiary Care Teaching Hospital: A Developing Country Scenario
Location: SP02
Pharmacovigilance
3:30 PM – 4:45 PM US Eastern Time
SP02C - Active Surveillance of Materiovigilance in a Tertiary Care Teaching Hospital: An Initiation of Clinical Pharmacist
Location: SP02
Medical Devices
3:30 PM – 4:45 PM US Eastern Time
SP02D - The Risk of Serious Infection in Rheumatoid Arthritis Patients Receiving Tocilizumab Compared with Tumor Necrosis Factor Inhibitors in Korea
Location: SP02
Biologics/Biosimilars
3:30 PM – 4:45 PM US Eastern Time
SP02E - Use of Antipsychotics and Cholinesterase Inhibitors and the Risk of Falls and Fractures
Location: SP02
Geriatric Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP02F - The Risk of Seizures Associated with the Use of Tramadol: A Nationwide Case-case-time-control Study
Location: SP02
Safety End Points
3:30 PM – 4:45 PM US Eastern Time
SP02G - Adherence to Medication: Patient Reported Facilitators and Barriers
Location: SP02
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP02H - The Association Between Influenza Vaccination and the Risk of Bell's Palsy in the Korean Elderly
Location: SP02
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP03 - Spotlight Posters: Biologics
3:30 PM – 4:45 PM US Eastern Time
SP03A - Spotlight Posters: Biologics
Location: SP03
3:30 PM – 4:45 PM US Eastern Time
SP03B - Colonoscopy Use After Treatment Initiation in US Commercially Insured Patients with Inflammatory Bowel Disease, 2013-2018
Location: SP03
Biologics/Biosimilars
3:30 PM – 4:45 PM US Eastern Time
SP03C - Incidence of Inpatient Constipation Among Migraine Patients Treated with Erenumab: A Retrospective Cohort Study in a US Electronic Health Record Database
Location: SP03
Safety End Points
3:30 PM – 4:45 PM US Eastern Time
SP03E - What Happened to Rheumatoid Arthritis Patients Who Stopped Biologic or Targeted Synthetic Disease Modifying Antirheumatic Therapy?
Location: SP03
Biologics/Biosimilars
3:30 PM – 4:45 PM US Eastern Time
SP03F - Utilisation and Treatment Patterns of Medicines to Manage Relapsing Remitting Multiple Sclerosis: Implications for Pharmacovigilance
Location: SP03
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP03G - Outpatient Transfusions and Occurrence of Febrile Non-hemolytic Transfusion Reactions Among U.S. Medicare Beneficiaries, Ages 65 and Older, During 2011-2018: Utility of Real-world Data
Location: SP03
Biologics/Biosimilars
3:30 PM – 4:45 PM US Eastern Time
SP03H - Direct Health Care Costs Among Patients with Rheumatoid Arthritis Before and After the Initiation of Treatment with Jaki in Tuscany: The LEONARDO Study
Location: SP03
Health Economics/Outcomes Research
3:30 PM – 4:45 PM US Eastern Time
SP03J - Risk of Serious Infection in Patients with Psoriasis: A Cohort Study of 44,239 Biologic-naïve Patients Using the French National Health Data System
Location: SP03
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP03K - Disease Severity and Outcomes Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic: Real-world US Experience with Sarilumab from the ACR RISE Registry
Location: SP03
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP04 - Spotlight Posters: BRACE
3:30 PM – 4:45 PM US Eastern Time
SP04 - Spotlight Posters: BRACE
Location: SP04
3:30 PM – 4:45 PM US Eastern Time
SP04A - A Scoping Review of Key Use Cases for Artificial Intelligence to Reduce the Frequency of Adverse Drug Events
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04B - Awareness of Isotretinoin Use and Saudi FDA Pregnancy Prevention Program in Riyadh, Saudi Arabia: A Cross-sectional Study Among Female Patients
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04C - Evaluating Physician Knowledge of Risks and Safe Use of Rivaroxaban
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04D - Challenges and Recommendations in Understanding National Guidance and Marketing Authorization Holder Experiences for Implementing Additional Risk Minimization Measures in the European Union and the United Kingdom
Location: SP04
Pharmacovigilance
3:30 PM – 4:45 PM US Eastern Time
SP04E - Efficacy and Safety of Isoniazid Preventive Therapy (IPT) in People Living with Hiv: A Systematic
review and Meta-analysis
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04F - Effectiveness of Direct Healthcare Professional Communication for Concentrated Insulin Lispro (U-200 Kwikpen) in France, Germany, and Sweden
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04G - Dermatologists Awareness and Compliance with Saudi FDA Isotretinoin Pregnancy Prevention Program in Saudi Arabia: A Cross-sectional Study
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04H - Saudi Fda-approved Risk Minimization Measures: A Descriptive Overview
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04J - Longitudinal Evaluation of U.S. REMS Program Modifications (2008–2020)
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP05 - Spotlight Posters: Cancer
3:30 PM – 4:45 PM US Eastern Time
SP05 - Spotlight Posters: Cancer
Location: SP05
3:30 PM – 4:45 PM US Eastern Time
SP05A - Outcomes in Patients (pts) with Advanced Basal Cell Carcinoma (aBCC) Who Discontinued First-line (1L) Hedgehog Inhibitors (HHI) Systemic Treatment (Tx) in a US Community Oncology Setting: A Retrospective Observational Study
Location: SP05
Health Economics/Outcomes Research
3:30 PM – 4:45 PM US Eastern Time
SP05B - Nonsteroidal Anti-inflammatory Drug Use and Skin Cancer Risk: A Prospective Cohort Study
Location: SP05
Disease Epidemiology/Clinical Course
3:30 PM – 4:45 PM US Eastern Time
SP05C - Non-interventional Post-authorization Safety Studies and Post-authorization Effectiveness Studies for Oncology Drugs: A Systematic Review
Location: SP05
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP05D - Lessons Learned in Predicting Gastric Cancer Survival Using Machine Learning
Location: SP05
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP05E - Real World Progression-free Survival in Patients with Advanced or Metastatic Urothelial Cancer Treated with First-line Platinum-based Chemotherapy
Location: SP05
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP05F - DNA Mismatch Repair and Microsatellite Instability in Colorectal Tumors: An Observational Study in the Veterans Affairs Health Care System
Location: SP05
Health Economics/Outcomes Research
3:30 PM – 4:45 PM US Eastern Time
SP05G - Comparison of the Risk of Cardiovascular Outcomes in Novel Hormonal Agents in Metastatic Castration-resistant Prostate Cancer
Location: SP05
Safety End Points
3:30 PM – 4:45 PM US Eastern Time
SP06 - Spotlight Posters: Comparative Effectiveness Research
3:30 PM – 4:45 PM US Eastern Time
SP06 - Spotlight Posters: Comparative Effectiveness Research
Location: SP06
3:30 PM – 4:45 PM US Eastern Time
SP06A - Comparative Effectiveness and Safety of Apixaban versus Rivaroxaban Among Patients with Non-valvular Atrial Fibrillation and Liver Disease: A Population-based Cohort Study
Location: SP06
Drug Effectiveness
3:30 PM – 4:45 PM US Eastern Time
SP06B - Misclassification of Obesity in Claims Data – Are Assumptions About Non-differential Misclassification Warranted?
Location: SP06
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP06E - Use of Negative Control Outcomes to Detect Mismeasured Confounders in Administrative Data
Location: SP06
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP06F - Perioperative Gabapentinoids and Risk of Postoperative Chronic Opioid Use Among Older Adults Undergoing Total Knee or Hip Arthroplasty
Location: SP06
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP06G - Best Practice Recommendations for the Design and Analyses of Pragmatic Clinical Trials: A Modified Delphi Method Study
Location: SP06
Drug Effectiveness
3:30 PM – 4:45 PM US Eastern Time
SP06H - Simulation-based Evaluation of Index Date Selection Methods with External Controls
Location: SP06
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP07 - Spotlight Posters: Databases
3:30 PM – 4:45 PM US Eastern Time
SP07 - Spotlight Posters: Databases
Location: SP07
3:30 PM – 4:45 PM US Eastern Time
SP07A - Information on the Socioeconomic Status in the German Pharmacoepidemiological Research Database: Completeness and Proof-of-concept Analysis
Location: SP07
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP07B - Novel Use of Harmonized Data Quality Indicators in Long-term Safety Studies Using Multiple Sclerosis Registries: Approach in CLARION Study
Location: SP07
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP07C - Performance of Different Definitions for COVID-19 Infection Across European Databases
Location: SP07
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP07D - Exposure Misclassification in Pharmacoepidemiology: Sources and Relative Impact
Location: SP07
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP07E - Validity of ICD-10 Heart Failure Administrative Codes Among the Elderly in the United States
Location: SP07
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP07F - A Cookbook for Estimating Treatment Duration from Databases of Routinely Collected Electronic Health Data Participating in Multi-source Studies
Location: SP07
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP07G - Validation of Acute Outcomes Among Patients with Type 2 Diabetes Mellitus in the Clinical Practice Research Datalink
Location: SP07
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP08 - Spotlight Posters: Digital Epidemiology
3:30 PM – 4:45 PM US Eastern Time
SP08 - Spotlight Posters: Digital Epidemiology
Location: SP08
3:30 PM – 4:45 PM US Eastern Time
SP08A - Who Will Develop Diabetes? A 5-year Risk Prediction Model for Antidiabetic Treatment Initiation in Individuals with hba1c-defined Prediabetes
Location: SP08
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP08B - Development of a Tool for Detecting Patient-level Symptoms in Relation with Medications Using Disease Blogs on the Internet
Location: SP08
Pharmacovigilance
3:30 PM – 4:45 PM US Eastern Time
SP08C - Comparing Two Geographic Sources of Patient Generated Health Data (PGHD) in a COVID-19 Registry (CARE): UK and US Symptomatology
Location: SP08
Informatics
3:30 PM – 4:45 PM US Eastern Time
SP08D - Use of a Mobile App to Capture Supplemental Health Information During Pregnancy: Implications for Clinical Research
Location: SP08
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP08E - Unpicking the Tangled Symptomatology of COVID19 Using an Interpretable Clustering Methodology
Location: SP08
Informatics
3:30 PM – 4:45 PM US Eastern Time
SP08F - Development and Validation of Real-world Prediction Models to Identify Individuals with Undiagnosed NASH
Location: SP08
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP08G - Use of a Natural Language Processing-based Approach to Extract Depression Symptom Severity and Suicide Ideation from Clinical Notes to Support Depression Research
Location: SP08
Informatics
Spotlight Posters 2
5:15 PM – 6:30 PM US Eastern Time
SP09 - Spotlight Posters: Drug Utilization Research
5:15 PM – 6:30 PM US Eastern Time
SP09 - Spotlight Posters: Drug Utilization Research
Location: SP09
5:15 PM – 6:30 PM US Eastern Time
SP09A - Impact of COVID-19 Outbreak on Anticoagulants Utilization: A Real-word Drug-utilization Study Based on Tuscany Healthcare Administrative Databases
Location: SP09
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP09B - Target Blood Pressure Levels and the Risk of Major Adverse Cardiovascular Events Among Patients with Hypertension at Low Cardiovascular Disease Risk
Location: SP09
Disease Epidemiology/Clinical Course
5:15 PM – 6:30 PM US Eastern Time
SP09C - Factors Associated with Initiation of Oral vs. Injectable Disease Modifying Therapies Among Multiple Sclerosis Patients: A Machine Learning Approach
Location: SP09
Informatics
5:15 PM – 6:30 PM US Eastern Time
SP09D - Drug Utilization Research in Africa: Key Research Challenges
Location: SP09
Drug Utilization Research
5:15 PM – 6:30 PM US Eastern Time
SP09E - The Impact of Regulatory Restrictions on the Use of Pregabalin: An Interrupted Time-series
Location: SP09
Drug Utilization Research
5:15 PM – 6:30 PM US Eastern Time
SP10 - Spotlight Posters: Drug-Drug Interaction
5:15 PM – 6:30 PM US Eastern Time
SP10 - Spotlight Posters: Drug-drug Interaction
Location: SP10
5:15 PM – 6:30 PM US Eastern Time
SP10A - Drug Utilization and Prescribing Pattern of Concomitant Use of Enzalutamide and Anticoagulation
Location: SP10
Drug Utilization Research
5:15 PM – 6:30 PM US Eastern Time
SP10B - Opioid Drug-drug-drug Interactions and Unintentional Traumatic Injury: Screening to Detect Three-way Drug Interaction Signals
Location: SP10
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP10C - Oral Contraceptive Failures in the Presence of a Drug-drug Interaction – Does Progestin Type Matter?
Location: SP10
Drug Effectiveness
5:15 PM – 6:30 PM US Eastern Time
SP10D - Concomitant Use of Direct Oral Anticoagulants and Antiplatelet Agents and the Risk of Major Bleeding and Death Among Patients with Venous Thromboembolism: Preliminary Results of a Population-based Multinational Cohort Study
Location: SP10
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP10E - Calcium Channel Blockers Used Concomitantly with Insulin Secretagogues and Serious Hypoglycemia
Location: SP10
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP10F - Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-based Screening Study
Location: SP10
Safety End Points
5:15 PM – 6:30 PM US Eastern Time
SP10G - COLCHICINE AND cyp3a4/p-gp INHIBITORS INTERACTION SIGNAL DETECTION USING FAERS
Location: SP10
Pharmacovigilance
5:15 PM – 6:30 PM US Eastern Time
SP10H - Acute Generalized Exanthematous Pustulosis (AGEP): Exploratory Analysis on Drug Combinations
Location: SP10
Pharmacovigilance
5:15 PM – 6:30 PM US Eastern Time
SP10J - Risk of Major Bleeding Associated with Concomitant Use of Selective Serotonin Reuptake Inhibitors and Oral Anticoagulants: Systematic Review and Meta-analysis
Location: SP10
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP11 - Spotlight Posters: Genomics
5:15 PM – 6:30 PM US Eastern Time
SP11 - Spotlight Posters: Genomics
Location: SP11
5:15 PM – 6:30 PM US Eastern Time
SP11A - Quantifying Concordance Between Electronic Health Record (EHR) and Comprehensive Genomic Profiling (CGP) Biomarker Status in a Linked Clinico-genomic Database (CGDB)
SP11D - Identification of Sex-specific Genetic Associations with Response to Opioid Analgesics: A Pharmacogenomics Wide Association Study Using the Mayo Clinic RIGHT Protocol
Location: SP11
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP11E - FDA regulatory routes and clinical post-marketing requirements for personalized medicines
SP12B - Potentially Inappropriate Medication Use and Time to Dementia: Does Dose Matter?
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12C - Opioid Utilization Among Older Adults in All Nordic Countries 2009-2018
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12D - Social Determinants of Health Status Trajectories in Older Adults - A National Panel Based Longitudinal Study
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12E - Postoperative Safety of Tramadol Among Older Adults Following Total Hip and Knee Arthroplasty
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12F - Potential Over-treatment and Over-testing Among Older Adults with Type-ii Diabetes in Canada: An Observational Retrospective Cohort Study
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12G - Longitudinal Patterns of Anticholinergic and Sedative Drug Load Among Older Adults
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12H - No Differential Risk of Cutaneous Small Vessel Vasculitis with Oral Anticoagulant Use Among Patients with Atrial Fibrillation
Location: SP12
Disease Epidemiology/Clinical Course
5:15 PM – 6:30 PM US Eastern Time
SP12J - Beta-adrenoceptor Antagonists and Risk of Parkinson’s Disease: Meta-analysis of Pharmacoepidemiological Studies
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12K - Patterns of Antidementia and Antipsychotic Medication Use Before and After Nursing Home Admission Among Residents with Alzheimer’s Disease
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP13 - Spotlight Posters: Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13 - Spotlight Posters: Medical Devices
Location: SP13
5:15 PM – 6:30 PM US Eastern Time
SP13A - Epidemiology of Skin Event Rates Among Users of Pumps for the Subcutaneous Administration of Drugs for Chronic Conditions Based upon the United Kingdom (UK) Clinical Practice Research Datalink (CPRD) GOLD
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13B - Real-world Safety and Efficacy of Same-day Discharge After Catheter Ablation for Atrial Fibrillation
Location: SP13
Health Economics/Outcomes Research
5:15 PM – 6:30 PM US Eastern Time
SP13C - The Associations Between Bariatric Surgery and Hip or Knee Arthroplasty, and Hip or Knee Osteoarthritis: A Cohort Study from Swedish Nationwide Healthcare Registries
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13D - Trends of Transcatheter Left Atrial Appendage Occlusion for Stroke Prevention in Atrial Fibrillation vs. the Use of Oral Anticoagulants
Location: SP13
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP13E - Population Testing for COVID-19: An Exemplary Approach for Ruling out False Positive Results
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13F - EXOGEN Mitigates Risk of Fifth Metatarsal Fracture Nonunion: Results of a Novel Real-world Clinical Study
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13G - Innovative Linkage of Device-generated Data to Electronic Medical Records
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13H - Association of Sex with Risk of 2-year Revision for Patients Undergoing Total Hip Arthroplasty
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13J - Completeness of 1-year Patient Follow-up in 3 Healthcare System Electronic Health Record Systems
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13K - Real World Utilization of Implantable Cardioverter-defibrillators by Care Setting Among Older Heart Failure Patients in the United States
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP14 - Spotlight Posters: Medications in Pregnancy and Lactation
5:15 PM – 6:30 PM US Eastern Time
SP14 - Spotlight Posters: Medications in Pregnancy and Lactation
Location: SP14
5:15 PM – 6:30 PM US Eastern Time
SP14A - Use of Interrupted Time-series Analysis to Characterize Antibiotic Prescription Fills Across Pregnancy – a Norwegian Nation-wide Cohort Study
Location: SP14
Pregnancy and Lactation
5:15 PM – 6:30 PM US Eastern Time
SP14C - Do Pregnant Women Use Pharmacological Treatment as Prescribed?
Location: SP14
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP14E - Risky Drug Prescribing in 1.8 Million French Pregnant Women: A Nationwide Study Based on Two Risk Classification Systems
Location: SP14
Pregnancy and Lactation
5:15 PM – 6:30 PM US Eastern Time
SP14F - The Use of Type 2 Diabetes Mellitus Medications During Pregnancy in the United States
Location: SP14
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP14G - Women of Reproductive Age in the COVID-19 Active Research Experience (CARE) Registry
Location: SP14
Pregnancy and Lactation
5:15 PM – 6:30 PM US Eastern Time
SP14H - Prenatal Exposure to Teratogenic Medications in the Era of Risk Evaluation and Mitigation Strategies (REMS)
Location: SP14
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
5:15 PM – 6:30 PM US Eastern Time
SP15 - Spotlight Posters: Pediatrics
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP15 - Spotlight Posters: Pediatrics
Location: SP15
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP15A - Risk of Serious Skin and Subcutaneous Tissue Disorders for Nimesulide Among the Pediatric Population: A Jeopardy Identified Through the Analysis of Global Individual Case Safety Reports
Location: SP15
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP15B - Psychiatric and Neurologic Diagnoses in Children on Psychotropic Treatment, a Real-world Data Study from Catalonia (Spain)
Location: SP15
Pediatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP15C - Treatment for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of Poisoning in Children and Adolescents
Location: SP15
Pediatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP15D - Persistent High Level of Paediatric Outpatient Prescriptions in France Between 2010 and 2019: A Nationwide Population-based Study
Location: SP15
Pediatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP15E - Early-life Infection and Antiinfectives Exposure and Prevalence of Overweight and Obesity in Danish Children
Location: SP15
Pediatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP15F - Scandinavian Discrepancies in Use of Hypnotic Drugs Among Children, Adolescents, and Young Adults
Location: SP15
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP15G - Timing of Congenital Malformation Diagnosis Relative to Delivery Date in a Commercially Insured Population of Pregnant Women and Infants
Location: SP15
Pediatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP15H - Children’s Relative Age and Medicine Treatment for Attention-deficit/hyperactivity Disorder (ADHD) Across Australian Jurisdictions with Different School Enrolment Policies
Location: SP15
Drug Utilization Research
5:15 PM – 6:30 PM US Eastern Time
SP16 - Spotlight Posters: Rare Diseases
5:15 PM – 6:30 PM US Eastern Time
SP16 - Spotlight Posters: Rare Diseases
Location: SP16
5:15 PM – 6:30 PM US Eastern Time
SP16A - Feasibility Assessment of Claims Databases for Pregnancy Outcomes
Location: SP16
Safety End Points
5:15 PM – 6:30 PM US Eastern Time
SP16B - A View into the Tay Sachs Variants’ Populations Using the GM2 Disease Registry
Location: SP16
Rare Disease
5:15 PM – 6:30 PM US Eastern Time
SP16C - Prevalence of Mammary Paget’s Disease in Urban China in 2016
Location: SP16
Rare Disease
5:15 PM – 6:30 PM US Eastern Time
SP16D - Burden of Comorbidities Among Adults with Concurrent Obesity and Heart Failure with Preserved Ejection Fraction
Location: SP16
Disease Epidemiology/Clinical Course
5:15 PM – 6:30 PM US Eastern Time
SP16E - Incidence of Steroid-related Damage in Korean Patients with Systemic Lupus Erythematosus, Compared to General Population, 2002-2015 : A Retrospective Cohort Study
Location: SP16
Rare Disease
5:15 PM – 6:30 PM US Eastern Time
SP16F - Prevalence of Focal Segmental Glomerular Sclerosis (FSGS) in the United States: Results from Electronic Healthcare Records Using Clinically Defined Algorithms
Location: SP16
Rare Disease
5:15 PM – 6:30 PM US Eastern Time
SP16G - Characteristics of a Prevalent SMA Population Drawn from a Patient Registry Network
Location: SP16
Rare Disease
5:15 PM – 6:30 PM US Eastern Time
SP16H - Incidence and Prevalence of Rhabdomyolysis in Patients with Type 2 Diabetes in the US
Location: SP16
Disease Epidemiology/Clinical Course
5:15 PM – 6:30 PM US Eastern Time
SP17 - Spotlight Posters: Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17F - Spotlight Posters: Drug Utilization Research
Location: SP17
5:15 PM – 6:30 PM US Eastern Time
SP17 - The Effect of Prioritization and Second Dose Interval Choice on the Effectiveness of COVID-19 Vaccination in Europe: An Agent-based Cohort Model
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17A - Seasonal Patterns in Vaccine Administration and Outcome Occurrence – a Potential Source of Artifact in Self-controlled Safety Study Designs
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17B - Pfizer-biontech Coronavirus Vaccine and the Risk of Anaphylaxis
Location: SP17
Pharmacovigilance
5:15 PM – 6:30 PM US Eastern Time
SP17C - New-onset Autoimmune Disease (AID) Detection and Validation in Healthcare Databases
Location: SP17
Safety End Points
5:15 PM – 6:30 PM US Eastern Time
SP17D - Anogenital Warts and the Introduction of the Quadrivalent HPV Vaccine Program in Manitoba, Canada
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17E - A Descriptive Retrospective Cohort Study to Establish Rates for Safety Outcomes of Interest (SOI) in Vaccine Development Programs
Location: SP17
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP17G - Assessment of Thyroiditis Risk Associated with HPV Vaccination Among Girls Aged 9-18 Years: A Time-varying Cohort Study
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17H - The Safety and Immunologic Effectiveness of the Live Varicella Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy: A Randomized Controlled Trial
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17J - Impact of 2011/2012 ACIP Maternal Pertussis Vaccination Recommendations on Infant Pertussis Mortality in the US
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17K - Validity of Claims-based Algorithms to Identify Patients with Test-positive Influenza
Location: SP17
Methods in Pharmacoepidemiology
Lightning Session 3
6:45 PM – 7:45 PM US Eastern Time
L-3 - Lightning Session 3
6:45 PM – 7:45 PM US Eastern Time
Lightning Session 3
Location: L-3
6:45 PM – 7:45 PM US Eastern Time
L-3A - Gender Differences in Valproic Acid Use for Approved Indications in the United States (2017-2018) – an Opportunity for Risk Mitigation?
Location: L-3
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
6:45 PM – 7:45 PM US Eastern Time
L-3B - Missingness in Real World Data Submitted for Regulatory Decision-making: Eastern Cooperative Oncology Group Performance Status Case Study
Location: L-3
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
6:45 PM – 7:45 PM US Eastern Time
L-3C - Association of Statin Use with Dry Eye Disease
Location: L-3
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
6:45 PM – 7:45 PM US Eastern Time
L-3D - A New Analytic Tool for Interrupted Times Series Analysis to Assess the Impact of FDA Regulatory Actions
Location: L-3
Methods in Pharmacoepidemiology
6:45 PM – 7:45 PM US Eastern Time
L-3D - Birth Prevalence of Phenylalanine Hydroxylase Deficiency: A Systematic Literature Review and Meta-analysis
Location: L-3
Disease Epidemiology/Clinical Course
6:45 PM – 7:45 PM US Eastern Time
L-3E - Use of Last Clinical Activity Date in Overall Survival Analysis with Real World Data
Location: L-3
Methods in Pharmacoepidemiology
6:45 PM – 7:45 PM US Eastern Time
L-3F - Distinguishing Death from Disenrollment in Claims Data Using a Readily Implemented Machine Learning Algorithm
Location: L-3
Methods in Pharmacoepidemiology
6:45 PM – 7:45 PM US Eastern Time
L-3G - Development and Validation of Case-finding Algorithms to Identify Prosthetic Joint Infections After Total Knee Arthroplasty
Location: L-3
Methods in Pharmacoepidemiology
6:45 PM – 7:45 PM US Eastern Time
L-3H - Analytical Enhancements in Kentucky’s Drug Overdose Mortality Surveillance: Rapid Monitoring of Trends and Decedents’ Recent Controlled Substance Prescription History
Location: L-3
Drug Utilization Research
6:45 PM – 7:45 PM US Eastern Time
L-3J - Measuring Mental Health Prescribing Safety Indicators in UK Primary Care
Location: L-3
Drug Utilization Research
6:45 PM – 7:45 PM US Eastern Time
L-3K - Pediatric Off-label Antipsychotic Use for Attention-deficit/hyperactivity Disorder: A Time-to-event Analysis
Location: L-3
Pediatric Pharmacoepidemiology
6:45 PM – 7:45 PM US Eastern Time
L-3M - Temporal Effect in Real-world-evidence for Randomized-clinical-trials
Location: L-3
Informatics
6:45 PM – 7:45 PM US Eastern Time
L-3N - The Risk of Melanoma with Rasagiline Compared with Other Antiparkinsonian Medications: A Retrospective Cohort Study in the United States Medicare Database
Location: L-3
Safety End Points
6:45 PM – 7:45 PM US Eastern Time
L-3P - Risk of Major Cardiovascular Event in Jak Inhibitor Treated Patients: Analysis of a National Claim Database
Location: L-3
Biologics/Biosimilars
Plenary 2 - Repeat
8:00 PM – 9:30 PM US Eastern Time
PLEN-2B - REPEAT: Communicating COVID-19 Pharmacoepidemiological Research to Patients: Why is it important? How can we do it? What are the implications now and for the future?
8:00 PM – 9:30 PM US Eastern Time
PLEN-2B - REPEAT: Communicating COVID-19 Pharmacoepidemiological Research to Patients: Why Is It Important? How Can We Do It? what Are the Implications Now and for the Future?
Location: PLEN-2B
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
Wednesday, August 25, 2021
8:15 AM – 8:30 AM US Eastern Time
DAY3 - Welcome Session
8:15 AM – 8:30 AM US Eastern Time
Welcome Session
Location: DAY3
6:00 PM – 6:30 PM US Eastern Time
CLOSE - Closing Ceremony
6:00 PM – 6:30 PM US Eastern Time
Closing Ceremony
Location: CLOSE
Plenary 3
8:30 AM – 10:00 AM US Eastern Time
PLEN-3 - COVID-19 Vaccines: Timely Global Real-World Evidence
8:30 AM – 10:00 AM US Eastern Time
PLEN-3 - COVID-19 Vaccines: Timely Global Real-world Evidence
Location: PLEN-3
Vaccines
Concurrent Session 4
10:00 AM – 11:30 AM US Eastern Time
CW12 - Concurrent Workshops 5
10:00 AM – 11:30 AM US Eastern Time
WS-12 - Pediatric Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV 2) and Potential Health Consequences (submitted on Behalf of the ISPE RWE covid-19 Workgroup)
Location: WS-12
Disease Epidemiology/Clinical Course
10:00 AM – 11:30 AM US Eastern Time
WS-14 - Product Surveillance and Signal Management: Now Is the Time for Methodologist Engagement!
Location: WS-14
Medical Devices
10:00 AM – 11:30 AM US Eastern Time
WS-16 - RWE Blueprints: Decoding SPACE, SPIFD, Start-rwe, and Other Tools Promoting Principled Pharmacoepidemiology
Location: WS-16
Methods in Pharmacoepidemiology
10:00 AM – 11:30 AM US Eastern Time
WS-17 - Selection Matters: Addressing Biases in Linked Clinico-genomic Data Sets
Location: WS-17
Methods in Pharmacoepidemiology
10:00 AM – 11:30 AM US Eastern Time
WS-18 - Strategies for the Use of Real-world Data to Conduct covid-19-related Pharmacoepidemiology
Location: WS-18
Methods in Pharmacoepidemiology
Oral Presentations Session 4
11:45 AM – 1:30 PM US Eastern Time
OP-02 - Brains or Bytes? In Search of Patterns
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Brains or Bytes? In Search of Patterns
Location: OP-02
11:45 AM – 1:30 PM US Eastern Time
OP-2A - Identifying Active Pregnancies Using ICD-10 Z3A Codes versus Completed Pregnancies Using Outcomes
Location: OP-02
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-2B - Prediction Algorithm for Identifying Patients with Fabry or Pompe Disease in Electronic Health Records
Location: OP-02
Rare Disease
11:45 AM – 1:30 PM US Eastern Time
OP-2C - The Impact of Longitudinal Data-completeness of Electronic Health Record (EHR) Data on Prognostic Risk Score Misclassification
Location: OP-02
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-2D - Leveraging Artificial Intelligence (AI) Technologies for Automated Identification of Total Knee Arthroplasty (TKA) Devices in Electronic Health Records
Location: OP-02
Medical Devices
11:45 AM – 1:30 PM US Eastern Time
OP-2E - Improving Methods of Identifying Anaphylaxis for Medical Product Safety Surveillance Using Natural Language Processing and Machine Learning
Location: OP-02
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-2F - Validation of an Algorithm to Identify Hormonal Contraceptive Exposure in a Large Integrated Health Care Delivery System Database
Location: OP-02
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-05 - COVID-19 Potpourri: Vaccines, Long Haulers, and the NFL
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: COVID-19 Potpourri: Vaccines, Long Haulers, and the NFL
Location: OP-05
11:45 AM – 1:30 PM US Eastern Time
OP-5A - Descriptive Epidemiology of Adverse Events of Special Interest for COVID-19 Vaccines Across 7 Countries and 4 Continents: A Multinational Network Cohort Study
Location: OP-05
Vaccines
11:45 AM – 1:30 PM US Eastern Time
OP-5B - Population Testing for COVID-19: Can a Rapid Antigen Test Rule out Infection?
Location: OP-05
Medical Devices
11:45 AM – 1:30 PM US Eastern Time
OP-5C - Impact of COVID-19 Social Distance Restrictions on Hospital Encounters Due to Injury by Poisoning or Toxicity of Medications or Non-medicinal Substances
Location: OP-05
Pharmacovigilance
11:45 AM – 1:30 PM US Eastern Time
OP-5D - Persistence of COVID-19 Symptoms 90 Days Post-acute Infection: Insights from a Community-based Registry
Location: OP-05
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-5E - Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized with COVID-19 in the United states:
results from the National COVID Cohort Collaborative (N3C)
Location: OP-05
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-5F - COVID-19 in Children: Treatment Patterns in the Real-world Hospital Setting
Location: OP-05
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-07 - Fast and Furious: Driving Down the Clinical Course of Disease Epidemiology
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Fast and Furious: Driving down the Clinical Course of Disease Epidemiology
Location: OP-07
11:45 AM – 1:30 PM US Eastern Time
OP-7A - Impact of Non-alcoholic Steatohepatitis (NASH) Case Definition on Population Characteristics Identified in a US Claims Database
Location: OP-07
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-7B - The Effect of Epidural Steroid Injections on Fracture Risk Among Medicare Patients
Location: OP-07
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-7C - Persistence of Anticoagulation After Receiving Transcatheter Left Atrial Appendage Occlusion vs. Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Location: OP-07
Medical Devices
11:45 AM – 1:30 PM US Eastern Time
OP-7D - Longitudinal Adherence Trajectories to Biologic Disease Modifying Anti-rheumatic Drugs in Tuscany, Italy
Location: OP-07
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-7E - Hyperthyroidism and Breast Cancer Recurrence and Mortality: A Danish Population-based Cohort Study
Location: OP-07
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-7F - Incidence Rates of Select Outcomes Among Patients with Non-alcoholic Steatohepatitis (NASH) and Evidence of Fibrosis and Cirrhosis
Location: OP-07
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-10 - Impact of Disparities and Stigma on Drug Access and Utilization
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Impact of Disparities and Stigma on Drug Access and Utilization
Location: OP-10
11:45 AM – 1:30 PM US Eastern Time
OP-10A - Disparities in Hepatitis C Treatment in the Era of Direct-acting Antivirals Among Arizona Medicaid Beneficiaries
Location: OP-10
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-10B - Sources of Racial/ethnic Disparities in Antidepressant Treatment: Analysis of the Medical Expenditure Panel Survey Data
Location: OP-10
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-10C - Do Medicare Part D Low-income Subsidies Narrow Disparities in Orally-administered Antimyeloma Therapy Initiation?
Location: OP-10
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-10D - Impact of Race, Ethnicity, and Sex on Treatment of Non-valvular Atrial Fibrillation
Location: OP-10
Health Economics/Outcomes Research
11:45 AM – 1:30 PM US Eastern Time
OP-10E - The Impact of Sex on the Quality of Medication Treatment in Patients with Type 2 Diabetes
Location: OP-10
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-10F - Changes in Buprenorphine Utilization During the COVID-19 Pandemic in the US
Location: OP-10
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-12 - Look Who's Talking Now: Capturing Patient and Provider Perspectives in Health Data
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Look Who's Talking Now: Capturing Patient and Provider Perspectives in Health Data
Location: OP-12
11:45 AM – 1:30 PM US Eastern Time
OP-12A - Participant Engagement and Adherence in an Arthritispower Real-world Study to Capture Smartwatch and Patient-reported Outcome Data Among Rheumatoid Arthritis Patients
Location: OP-12
Health Economics/Outcomes Research
11:45 AM – 1:30 PM US Eastern Time
OP-12B - Ranitidine and Other histamine2-receptor Antagonists – a Rapid Response Drug Utilisation Study Using Electronic Health Care Data from Six European Countries
Location: OP-12
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-12C - The Friends of Cancer Research Real World Data (RWD) Pilot 2.0 Collaboration: Implementation of Standardized Methodological Approaches for Evaluation of Oncology RWD
Location: OP-12
Health Economics/Outcomes Research
11:45 AM – 1:30 PM US Eastern Time
OP-12D - Cost-effectiveness of Systematic Treatments for Metastatic Castration-sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-analysis
Location: OP-12
Health Economics/Outcomes Research
11:45 AM – 1:30 PM US Eastern Time
OP-12E - Telemedicine Use Among U.S. Patients with Cancer During the COVID-19 Pandemic
Location: OP-12
Health Economics/Outcomes Research
11:45 AM – 1:30 PM US Eastern Time
OP-12F - Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Location: OP-12
Drug Effectiveness
11:45 AM – 1:30 PM US Eastern Time
OP-16 - Pregnancy: Beyond opioids
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Pregnancy: Beyond Opioids
Location: OP-16
11:45 AM – 1:30 PM US Eastern Time
OP-16A - First Trimester Exposure to Buprenorphine Compared to Methadone for Treatment of Opioid Use Disorders and the Risk of Congenital Malformations
Location: OP-16
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-16B - Characteristics of Initial Postpartum Opioid Prescribing and Risks of Serious Opioid-related Events After Cesarean Delivery
Location: OP-16
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-16C - Prescription Opioid Type and the Risk of Neonatal Opioid Withdrawal Syndrome
Location: OP-16
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-16D - Benzodiazepine Use in the First Trimester and Risk of Congenital Malformations: A Nationwide Cohort Study in South Korea
Location: OP-16
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-16E - Comparative Safety of In-utero Exposure to Buprenorphine Combined with Naloxone versus Buprenorphine Monoproduct with Respect to Congenital Malformations
Location: OP-16
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-16F - Prenatal Analgesic Opioid Exposure and Risk of ADHD in Childhood
Location: OP-16
Pregnancy and Lactation
Annual Members Meeting/Awards Ceremony
1:45 PM – 2:45 PM US Eastern Time
MBMT - Annual Members Meeting/Awards Ceremony
1:45 PM – 2:45 PM US Eastern Time
Annual Members Meeting/awards Ceremony
Location: MBMT
Oral Presentations Session 5
3:00 PM – 4:30 PM US Eastern Time
OP-08 - From Patient to Policy Impact: Benefit-Risk Assessment, Communication, and Evaluation (BRACE) SIG
3:00 PM – 4:30 PM US Eastern Time
Oral Papers: From Patient to Policy Impact: Benefit-risk Assessment, Communication, and Evaluation (BRACE) SIG
Location: OP-08
3:00 PM – 4:30 PM US Eastern Time
OP-8A - Impact of Fda’s Regulatory Actions on the Quality of REMS Survey Methodology Protocols (2007 – 2020)
Location: OP-08
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:00 PM – 4:30 PM US Eastern Time
OP-8B - Influence of Drug Safety Advisories on Drug Utilization: An International Interrupted Time Series and Meta-analysis Study
Location: OP-08
Drug Utilization Research
3:00 PM – 4:30 PM US Eastern Time
OP-8C - Preferences Concerning Drug Safety Communication of Hospital-based Specialist in the Netherlands
Location: OP-08
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:00 PM – 4:30 PM US Eastern Time
OP-8D - Regulatory Approval of Phentermine/topiramate for Obesity Management and Off-label Use of Topiramate: A Fairytale for Drug Repurposing and a Maze for Risk Mitigation
Location: OP-08
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:00 PM – 4:30 PM US Eastern Time
OP-8E - What Matters to Patients When Considering Treatments for Prevention of Rheumatoid Arthritis: A Preference Study in the United Kingdom, Germany, and Romania
Location: OP-08
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:00 PM – 4:30 PM US Eastern Time
OP-13 - MedTech Globetrotting - Assisting Medical Devises Effects in the Real World
3:00 PM – 4:30 PM US Eastern Time
Oral Papers: Medtech Globetrotting - Assisting Medical Devises Effects in the Real World
Location: OP-13
3:00 PM – 4:30 PM US Eastern Time
OP-13A - Real-world Epidemiologic and Genetic Evidence Synthesis Reveals the Sex-dependent Role of GNAS Snps in Hip Arthroplasty Related Periprosthetic Osteolysis
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-13B - The Association Between Bariatric Surgery and Carpal Tunnel Syndrome: A Cohort Study from Swedish Nationwide Healthcare Registries
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-13C - Comparison of 10- and 15-year Outcomes of Bioprosthetic and Mechanical Aortic Valve Replacement in Patients Aged Under 65 Years: Australian Study Using Linked Data for 4,704 Patients
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-13D - Sex-differences in Risk of Early Revision After Primary Total Knee Arthroplasty
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-13E - The Association Between Bariatric Surgery and Cataract: A Cohort Study from Swedish Nationwide Healthcare Registries
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-13F - Comparative Patient Characteristics of Transcatheter Left Atrial Appendage Occlusion vs. Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-21 - Psychotropics: Bitter Pills to Swallow in Pregnancy
3:00 PM – 4:30 PM US Eastern Time
Oral Papers: Psychotropics: Bitter Pills to Swallow in Pregnancy
Location: OP-21
3:00 PM – 4:30 PM US Eastern Time
OP-21A - Prenatal Antiseizure Medication Exposure and Risk of Autism and Intellectual Disability. SCAN-AED: A Nordic Cohort Study
Location: OP-21
Pregnancy and Lactation
3:00 PM – 4:30 PM US Eastern Time
OP-21B - The Comparative Safety of Antiseizure Medication Polytherapy versus Valproate in Pregnancy and Risk of Major Congenital Malformations
Location: OP-21
Pregnancy and Lactation
3:00 PM – 4:30 PM US Eastern Time
OP-21C - Antidepressant Use During Pregnancy and the Risk of Neurodevelopmental Disorders in Children
Location: OP-21
Pregnancy and Lactation
3:00 PM – 4:30 PM US Eastern Time
OP-21D - The Impact of In-utero Antipsychotic Drug Exposure on Congenital Malformations: An International Cohort Study
Location: OP-21
Pregnancy and Lactation
3:00 PM – 4:30 PM US Eastern Time
OP-21F - The Impact of In-utero Antipsychotic Exposure on Neurodevelopmental Disorders in Children
Location: OP-21
Pregnancy and Lactation
3:00 PM – 4:30 PM US Eastern Time
PP-01 - Potpourri
3:00 PM – 4:30 PM US Eastern Time
PP-01 - Oral Presentations Potpourri
Location: PP-01
3:00 PM – 4:30 PM US Eastern Time
PP-01A - Approach to Falsify Calendar Time Instrumental Variable Assumptions in Estimating Treatment Effects
Location: PP-01
3:00 PM – 4:30 PM US Eastern Time
PP-01B - Risk of Fall-related Injury Associated with Concomitant Use of Prescription Opioids and Gabapentinoids Among Older Adults with Chronic Noncancer Pain
Location: PP-01
3:00 PM – 4:30 PM US Eastern Time
PP-01C - Ethnic Differences in COVID-19 Infection, Hospitalisation, and Mortality: An Opensafely Analysis of 17 Million Adults in England
Location: PP-01
Disease Epidemiology/Clinical Course
3:00 PM – 4:30 PM US Eastern Time
PP-01D - Nondifferential Treatment Misclassification Biases Toward the Null? Not a Safe Bet
Location: PP-01
Drug Utilization Research
3:00 PM – 4:30 PM US Eastern Time
PP-01E - Multi-depth, Iterative Causal Forest for Subgroup Identification
Location: PP-01
Disease Epidemiology/Clinical Course
3:00 PM – 4:30 PM US Eastern Time
PP-01F - Predictors of Severe COVID-19 Outcome in Patients with Rheumatoid Arthritis
Location: PP-01
Pharmacovigilance
Oral Presentations Session 6
4:30 PM – 6:00 PM US Eastern Time
OP-01 - Application of Pharmacoepidemiologic Study Designs for Research Across the Cancer Continuum
4:30 PM – 6:00 PM US Eastern Time
Oral Papers: Application of Pharmacoepidemiologic Study Designs for Research Across the Cancer Continuum
Location: OP-01
4:30 PM – 6:00 PM US Eastern Time
OP-1A - Proton Pump Inhibitors and Risk of Gastric Cancer: A Population-based Cohort Study
Location: OP-01
Safety End Points
4:30 PM – 6:00 PM US Eastern Time
OP-1B - Efficacy and Safety of Treatments for Nonmetastatic Castration-resistant Prostate Cancer: A Matching-adjusted Indirect Comparison and Network Meta-analysis
Location: OP-01
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-1C - Comparative Safety of Conjugated Estrogens/bazedoxifene (CE/BZA) versus Estrogen/progestin Combination Hormone Therapy (EP): A Multi-database Cohort Study
Location: OP-01
Safety End Points
4:30 PM – 6:00 PM US Eastern Time
OP-1D - Risk of Malignancies in Newly Treated Patients with Disease-modifying Drugs for Multiple Sclerosis: Assessment According to Cohort and Nested-case Control Approaches
Location: OP-01
Methods in Pharmacoepidemiology
4:30 PM – 6:00 PM US Eastern Time
OP-1E - Vitamin K Antagonists and Risk of Myelodysplastic Syndrome: A Nationwide Cohort Study in Atrial Fibrillation Patients
Location: OP-01
Safety End Points
4:30 PM – 6:00 PM US Eastern Time
OP-1F - Use of Proton Pump Inhibitors and Risk of Pancreatic Adenocarcinoma: A Case-control Study Based on the French National Health Data System (SNDS)
Location: OP-01
Safety End Points
4:30 PM – 6:00 PM US Eastern Time
OP-11 - Just How Well Does it Work in Real Life?
4:30 PM – 6:00 PM US Eastern Time
Oral Papers: Just How Well Does It Work in Real Life?
Location: OP-11
4:30 PM – 6:00 PM US Eastern Time
OP-11A - Calibrating Real-world Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Inflammatory Bowel Disease
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-11B - Shorter Drug Holiday After 3 or More Years of Risedronate versus Alendronate Is Important to Maintain Osteoporotic Fracture Protection
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-11C - Cardiovascular Effectiveness of SGLT-2 Inhibitors versus Metformin as First-line Treatment for Type 2 Diabetes
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-11D - Effect of SGLT-2 Inhibitors on Egfr in Type 2 Diabetes with Different Baseline Renal Functions: A Multi-center Study
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-11E - Comparative Effectiveness of Empagliflozin in Reducing Total Cardiovascular Events in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-11F - Initiation of Sodium‐glucose Co‐transporter 2 Inhibitors and Progression of Renal Disease Among Patients with type-2 Diabetes: A Population-based Cohort Study
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-17 - Pregnancy: Diabetes and a surprise
4:30 PM – 6:00 PM US Eastern Time
Oral Papers: Pregnancy: Diabetes and a Surprise
Location: OP-17
4:30 PM – 6:00 PM US Eastern Time
OP-17A - Characteristics and Outcomes of Pregnancies in Women with Heart Failure: A Retrospective Cohort Study in the Sentinel System
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-17B - Metformin and Risk of Adverse Pregnancy Outcomes Among Pregnant Women with Gestation Diabetes in the United Kingdom: A Population-based Cohort Study
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-17C - The Role of Propensity Score Matching in Claims-based Studies for Achieving Comparability in hba1c Levels Between Treatments in Pregnant Women with Type 2 Diabetes
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-17D - Balance of Unmeasured Covariates After Propensity Score Matching Based on Measurable Covariates in Perinatal Pharmacoepidemiologic Studies
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-17E - Development and Validation of ICD-10 Claims-based Algorithms for Pregnancy and Infant Outcomes
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-17F - Metformin versus Insulin in Early Pregnancy and Risk of Congenital Malformations
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-20 - PS I love you, XXII
4:30 PM – 6:00 PM US Eastern Time
Oral Papers: PS I Love You, XXII
Location: OP-20
4:30 PM – 6:00 PM US Eastern Time
OP-20A - Evaluating When Effect Estimates Change After Propensity Score Trimming Because of Differing Effect Measure Modifier Distributions
Location: OP-20
Methods in Pharmacoepidemiology
4:30 PM – 6:00 PM US Eastern Time
OP-20B - Optimization-based Stable Balancing Weights vs. Generalized Boosted Modeling for Propensity Score Weighting
Location: OP-20
Methods in Pharmacoepidemiology
4:30 PM – 6:00 PM US Eastern Time
OP-20C - Controlling for Differential Regression to the Mean Using Summary Measures of Pre-treatment Laboratory Values in Propensity Scores
Location: OP-20
Methods in Pharmacoepidemiology
4:30 PM – 6:00 PM US Eastern Time
OP-20D - An Evaluation of Direct and Propensity Score Matching versus Propensity Score Stratification for Confounding Adjustment in Primary Total Hip Arthroplasty
Location: OP-20
Medical Devices
4:30 PM – 6:00 PM US Eastern Time
OP-20E - Disease Risk Score as Alternative to Propensity Score Under Multiple Confounders and High Prevalence of Outcome: A Simulation Study Motivated by the Emergence of Multiple Repurposed Medicines During the COVID-19 Pandemic
Location: OP-20
Methods in Pharmacoepidemiology
4:30 PM – 6:00 PM US Eastern Time
OP-20F - Cardinality Matching vs Propensity Score Matching in Multiple Sclerosis
Location: OP-20
Methods in Pharmacoepidemiology
Plenary 3- Repeat
8:00 PM – 9:30 PM US Eastern Time
PLEN-3B - REPEAT: COVID-19 Vaccines: Timely Global Real-World Evidence
8:00 PM – 9:30 PM US Eastern Time
PLEN-3B - REPEAT: COVID-19 Vaccines: Timely Global Real-world Evidence
